Abbott Medical Optics Points to Leadership Position

Over the past year, Abbott Medical Optics (AMO) has established a leading share position in the US PC-IOL market, driven by the new low-add-power Tecnis Multifocal IOLs. Outside the US, the early success of the Tecnis Symfony Extended Range of Vision IOL has also contributed to market share gains. A large European multicenter post-market study of Symfony, involving more than 600 patients, has confirmed excellent visual outcomes with this lens.

Leonard Borrmann, divisional vice president of R&D for AMO, noted that Abbott’s approach across the Tecnis Multifocal family is to provide a range of IOL options to meet diverse patient needs, delivering high-quality vision (20/25 or better) throughout the full range of distance, intermediate, and near. With respect to enhanced functionality for patients, the low-add-power Tecnis Multifocal +2.75 D IOL delivers full and partial spectacle independence in 61% and 38% of patients, respectively. More than 90% of patients with this lens report no difficulty with night vision, similar to a Tecnis monofocal IOL, and 97% of patients report that they would choose to have the same IOL again. Beyond improving multifocal IOL technology, Abbott is also working to expand the premium channel through surgeon training and education, patient awareness programs, and creation of new premium IOL categories, such as extended range of vision.


Leonard Borrmann

Leonard Borrmann

Leonard joined Abbott as Divisional Vice President R&D, in February 2009, with the acquisition of Advanced Medical Optics. During his five years with Advanced Medical Optics, he held positions of increasing responsibility in R&D concluding with Executive Vice President R&D.

View Full Profile